Save Product
Product Details
FAB
- Comprehensive validation - Validated with various antibody drugs.
- Simple and fast operation - No complicated washing steps, significantly reducing time.
- High batch consistency - Strict control over raw materials and finished product quality, ensuring a stable supply.
- Accurate and reliable results - High sensitivity with minimal matrix effects.
- High throughput capability - Support multiple product specifications, ideal for high-throughput screening.
- Fast completion - Results in just 1 hour.
Product Specifications
Assay TypeCompetition-TR-FRETReactivityHumanRegulatory StatusRUOAssay Time1 hrSample volume10 μLProduct Overview
The Human PD-1 / PD-L1 Inhibitor Screening Kit (TR-FRET) is based on a homogeneous (no wash) competition TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer) to screening for inhibitors of human PD-1 binding to PD-L1 within 0.5-1 hours. It can also be used as a universal detection tool to identify the ability of human PD-1 to bind to human PD-L1.
Storage
1. Unopened kit should be stored at 2℃-8℃ upon receiving.
2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
Materials Provided
IDComponentsSizeFRTP019-C01Human PD-L1 Protein Europium-chelate100 tests/500 testsFRTP019-C02FA Labeled Human PD-1 Protein100 tests/500 testsFRTP019-C03Anti-PD-L1 Antibody30 μg/100 tests 150 μg/500 testsDB-04TR-FRET Sample Dilution Buffer, pH7.450 mL/100 tests & 500 testsDB-05TR-FRET Detection Buffer, pH7.450 mL/100 tests & 500 testsAssay Principles
This Human PD-1 / PD-L1 Inhibitor Screening Kit (TR-FRET) is based on TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer). Use a mixture of biotinylated human PD-L1 and Europium-chelate labeled streptavidin as the donor and FA labeled human PD-1 as the acceptor.
— In the absence of inhibitors for human PD-L1 binding to human PD-1, the donor and acceptor are in close proximity due to the binding of human PD-L1 and human PD-1. Upon excitation with a specific light source, the donor emits a 620 nm signal, which is absorbed by the acceptor, resulting in a 665 nm emission.
— In the presence of inhibitors that block the binding of human PD-L1 to human PD-1, the donor-acceptor interaction is disrupted, preventing FRET from occurring.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-TR-FRET
Please refer to DS document for the assay protocol.
Inhibition of Europium-chelate labeled Human PD-L1 Protein : FA Labeled Human PD-1 Protein binding by Anti-PD-L1 Antibody
Premix serial dilutions of Anti-PD-L1 Antibody (1:2 serial dilution, from 4 μg/mL to 0.0039 μg/mL (26.667-0.026 nM)) and PD-L1 Protein Europium-chelate. Then add FA Labeled Human PD-1 Protein and incubate at room temperature (20℃-25℃) for 1 hours. Detection was performed with IC50 of 1.822nM. The assay was performed according to the above-described Datasheet (QC tested).
The kit is suitable for the detection of PD1/PD-L1 inhibitors. It shows that both Atezolizumab, Nofazinlimab and Pembrolizumab exhibit good inhibitory activity in this TR-FRET competition assay.
Customer Reviews Writing Reviews
Recent Advances
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
